IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.900
EU - Europa 11.660
AS - Asia 7.015
SA - Sud America 1.055
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 162
OC - Oceania 32
Totale 36.068
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.694
CN - Cina 2.639
GB - Regno Unito 2.434
SG - Singapore 2.147
RU - Federazione Russa 2.047
IE - Irlanda 1.540
IT - Italia 1.451
UA - Ucraina 1.152
BR - Brasile 885
SE - Svezia 864
FR - Francia 808
DE - Germania 721
VN - Vietnam 579
HK - Hong Kong 568
KR - Corea 363
FI - Finlandia 354
IN - India 162
BD - Bangladesh 124
ZA - Sudafrica 119
CA - Canada 113
AR - Argentina 58
ES - Italia 55
TR - Turchia 55
IQ - Iraq 52
MX - Messico 50
NL - Olanda 48
PL - Polonia 40
PK - Pakistan 36
ID - Indonesia 34
SA - Arabia Saudita 33
JP - Giappone 32
NG - Nigeria 31
AU - Australia 27
MA - Marocco 26
BE - Belgio 24
EC - Ecuador 24
CI - Costa d'Avorio 23
CL - Cile 23
UZ - Uzbekistan 20
VE - Venezuela 20
AT - Austria 19
PH - Filippine 17
CZ - Repubblica Ceca 16
IR - Iran 16
AE - Emirati Arabi Uniti 15
EU - Europa 15
MY - Malesia 15
CO - Colombia 14
NP - Nepal 13
KE - Kenya 11
DK - Danimarca 10
JO - Giordania 10
LT - Lituania 10
CR - Costa Rica 9
JM - Giamaica 9
PY - Paraguay 9
TH - Thailandia 9
BG - Bulgaria 8
PE - Perù 8
TW - Taiwan 8
UY - Uruguay 8
AZ - Azerbaigian 7
LB - Libano 7
OM - Oman 7
RO - Romania 7
TN - Tunisia 7
EG - Egitto 6
KZ - Kazakistan 6
AL - Albania 5
IL - Israele 5
NZ - Nuova Zelanda 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
MD - Moldavia 4
PS - Palestinian Territory 4
PT - Portogallo 4
QA - Qatar 4
AM - Armenia 3
BO - Bolivia 3
CH - Svizzera 3
EE - Estonia 3
GR - Grecia 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
MM - Myanmar 3
NI - Nicaragua 3
PA - Panama 3
RS - Serbia 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CD - Congo 2
Totale 35.881
Salva come PNG Salva come JPEG
Città #
Southend 2.112
Dallas 1.828
Dublin 1.523
Fairfield 1.506
Singapore 1.213
Ashburn 1.206
Chandler 979
Jacksonville 937
Woodbridge 772
Santa Clara 664
Wilmington 640
Seattle 620
Houston 581
Beijing 577
Moscow 565
Hong Kong 542
Milan 522
San Jose 492
Cambridge 477
Hefei 434
Council Bluffs 369
Seoul 359
Nanjing 345
Ann Arbor 343
New York 311
Princeton 311
The Dalles 288
Los Angeles 198
Ho Chi Minh City 176
Lauterbourg 171
Rome 168
Siena 153
San Mateo 148
Hanoi 138
Boardman 134
Helsinki 119
Nanchang 113
Munich 112
Johannesburg 103
Buffalo 96
San Diego 92
São Paulo 65
Shanghai 63
Dong Ket 61
Columbus 60
Changsha 50
Hebei 49
Shenyang 48
Tianjin 48
Redondo Beach 47
Figino 46
Norwalk 46
Kunming 45
Turku 43
Bengaluru 40
Frankfurt am Main 40
London 39
Orem 39
Toronto 39
Jiaxing 36
San Francisco 36
Turin 33
Málaga 32
Warsaw 32
Rio de Janeiro 31
Abuja 29
Guangzhou 28
Lancaster 28
Montreal 28
Tokyo 28
Brooklyn 27
Zhengzhou 26
Amsterdam 25
Boston 25
Hangzhou 25
Ningbo 25
Brussels 24
Chicago 24
Naples 24
Abidjan 22
Belo Horizonte 22
Chennai 22
Haiphong 22
Atlanta 21
Da Nang 21
Washington 21
Baghdad 20
Düsseldorf 20
Jinan 20
Tashkent 20
Nuremberg 19
Fremont 18
Denver 17
Dhaka 17
Philadelphia 17
Phoenix 17
Manchester 16
Menlo Park 16
Stockholm 16
Auburn Hills 15
Totale 24.270
Salva come PNG Salva come JPEG
Nome #
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 357
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 340
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 336
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 322
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 322
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 319
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 309
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 300
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 299
70 Tumor associated hypercalcemia 295
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 288
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 268
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 268
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer 267
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 267
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 266
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 266
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 264
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 262
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 260
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 259
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 258
Dendritic cell-cediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 258
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 251
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 248
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 242
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 241
Bioactivity of GM-CSF and IL-2 in cancer patients 241
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 239
Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 239
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 238
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mytomicin C 236
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 236
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 236
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 225
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 225
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 225
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 225
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 224
A Poly-epitopic peptide vaccine against the thymidylate synthase (TS). A synergistic therapeutic combination with fluoropyrimidine-based-chemotherapy 221
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 221
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 219
GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. 219
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 218
Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study 218
Quality of life in advanced colorectal cancer 218
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 217
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 216
Hepatoid gastric carcinoma. A case report 213
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study: TILs for ADJ-untreated stage II colon cancer 213
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 212
Analgesic activity and side effects of different calcitonins in man 212
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 211
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 209
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 209
Chemo-immunotherapy of colo-rectal cancer: Drug induced antigen specific cell-mediated immune response in vitro and in cancer patients 208
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer 208
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 207
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 206
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 206
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 206
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 204
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 202
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 201
Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man 200
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 199
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials 197
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 196
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 190
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 190
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 190
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 189
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 188
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 188
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 186
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 184
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 184
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 183
Analgesic effect of salmon calcitonin nasal pray on bone pain 183
Palliative chemotherapy for relief of subocclusive symptoms 182
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 182
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 182
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 182
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care 181
Seasonal variation in urinary excretion of cyclic AMP in healthy people 180
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 180
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 180
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 180
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 180
Osteoblastic metastases: Metabolic and morphologic aspects 178
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 174
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 174
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 173
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 173
Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 172
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 172
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab 171
Effects of tiapride and sulpiride infusions on plasma levels of beta-endorphin, prolactin and dopamine in patients with neoplastic pain 171
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 168
Weekly epirubicin in patients with hormone-resistant prostate cancer 165
Totale 22.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.121 0 300 193 179 95 59 96 91 122 246 230 510
2022/20233.467 225 201 427 519 346 758 56 318 386 59 113 59
2023/20242.217 111 58 165 69 61 725 741 39 2 47 44 155
2024/20254.369 107 274 297 252 516 202 74 216 375 164 517 1.375
2025/202611.197 861 1.731 1.338 1.025 1.910 428 1.243 326 389 593 288 1.065
2026/2027794 430 364 0 0 0 0 0 0 0 0 0 0
Totale 36.068